Capricor Therapeutics faces high regulatory risks for its DMD therapy. Get expert analysis on trial data and FDA challenges.
Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...
Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” ...
Just last week, Shkreli had identified Capricor as his next major biotech short target, co-authoring a lengthy report and ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...
Fintel reports that on December 8, 2025, Oppenheimer maintained coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...
In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...
Capricor Therapeutics said Wednesday that its cell therapy significantly improved muscle and heart function in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback